XML 285 R39.htm IDEA: XBRL DOCUMENT v3.25.3
Business Combination and Divestitures - Additional Information (Details)
$ / shares in Units, $ in Millions
2 Months Ended 3 Months Ended 9 Months Ended
Jul. 31, 2025
USD ($)
$ / shares
shares
Jun. 17, 2025
USD ($)
Nov. 29, 2024
USD ($)
Sep. 26, 2025
USD ($)
$ / shares
Sep. 26, 2025
USD ($)
$ / shares
Sep. 27, 2024
USD ($)
Sep. 26, 2025
USD ($)
segment
$ / shares
Sep. 27, 2024
USD ($)
Nov. 10, 2025
$ / shares
shares
Dec. 27, 2024
USD ($)
$ / shares
Feb. 02, 2024
Business Acquisition [Line Items]                      
Number of reportable segments | segment             3        
Goodwill       $ 7.3 $ 7.3   $ 7.3     $ 0.0  
Combination, integration, and other related expenses           $ 0.0 136.9 $ 0.0      
Liabilities management and separation costs         $ 33.3 15.2 $ 36.9 32.2      
Preferred shares, par value (in usd per share) | $ / shares       $ 0.01 $ 0.01   $ 0.01     $ 0.01  
Payments related to divestitures (Note 3)             $ 6.2        
Transition services agreement term             18 months        
Transaction services agreement revenue         $ 1.6   $ 6.8        
Subsequent Event                      
Business Acquisition [Line Items]                      
Preferred shares, par value (in usd per share) | $ / shares                 $ 0.001    
Shares of stock acquired in separation (in shares) | shares                 39,421,398    
Redemption date, percentage of shares acquired                 1    
Tranche One                      
Business Acquisition [Line Items]                      
Percent of award delivered                     50.00%
Tranche Two                      
Business Acquisition [Line Items]                      
Percent of award delivered                     50.00%
Tranche Three                      
Business Acquisition [Line Items]                      
Percent of award delivered                     100.00%
Par Health | Subsequent Event                      
Business Acquisition [Line Items]                      
Preferred shares, par value (in usd per share) | $ / shares                 $ 0.01    
International Pharmaceutical Business | Disposal Group, Disposed of by Sale, Not Discontinued Operations | Endo                      
Business Acquisition [Line Items]                      
Proceeds from divestiture   $ 89.9     2.4            
Divestiture consideration   78.6                  
Divestiture consideration, holdback   $ 11.3   $ 9.5 9.5   9.5        
Divestiture consideration, inventory true-up         0.5            
Divestiture consideration, employee termination         1.9            
Divestiture consideration, contingent milestones       15.0 15.0   15.0        
Therakos Divestiture                      
Business Acquisition [Line Items]                      
Proceeds from divestiture     $ 887.6       881.4        
Transaction Incentive Plan | Therakos Divestiture                      
Business Acquisition [Line Items]                      
Participant compensation paid after 12 months         15.6            
Compensation expense         9.5 $ 7.3 12.9 $ 7.3      
Accrued payroll and related costs                   $ 2.7  
Mallinckrodt & Endo Merger                      
Business Acquisition [Line Items]                      
Share exchange ratio (in shares) | shares 0.2575                    
Cash paid per share (in dollars per share) | $ / shares $ 1.31                    
Acquiree net sales       274.5              
Acquiree net loss       $ 155.0              
Goodwill $ 7.3                    
Combination, integration, and other related expenses         93.8   136.9        
Business combination, severance related costs         44.1            
Mallinckrodt & Endo Merger | Transaction Incentive Plan                      
Business Acquisition [Line Items]                      
Participant compensation paid after 12 months         $ 99.3   $ 99.3